Recital 5, Regulation (EU) 2026/743

In forcesince 30 Mar 2026

Taking into account the Authority’s conclusions, it is appropriate to allow the placing on the market of infant and follow-on formula manufactured from the specific protein hydrolysate. Therefore, it is appropriate to add ‘Protein-related requirements group F’ to the compositional requirements for protein hydrolysates set out in Delegated Regulation (EU) 2016/127.